33
Participants
Start Date
January 31, 2012
Primary Completion Date
October 31, 2012
Study Completion Date
October 31, 2012
IV morphine sulfate or Sponsor-approved equivalent
Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.
EXPAREL
Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
Florida Hospital d/b/a Colon & Rectal Surgery Center, Orlando
University of South Florida, Tampa
University of Arizona College of Medicine, Tucson
Lead Sponsor
Registrat-Mapi
OTHER
Pacira Pharmaceuticals, Inc
INDUSTRY